OBJECTIVES: To evaluate survival and outcomes after percutaneous radiofrequency ablation (RFA) of malignant renal tumours in high-risk patients with long-term follow-up. METHODS: Between 2002 and 2009, 62 patients (71 tumours), with a median age of 73.5 years (20-87), consecutively treated with RFA under ultrasound or computed tomography guidance for malignant renal tumours were retrospectively selected and prospectively followed until 2012, including 25 patients (40.3 %) with solitary kidney and 7 cystic cancers. Maximal tumour diameters were between 8 and 46 mm (median: 23 mm). RESULTS: Radiofrequency ablation was technically possible for all patients. Mean follow-up was 38.8 months (range: 18-78 months). Primary and secondary technique effectiveness was 95.2 % and 98.4 % per patient respectively. The rates of local tumour progression and metastatic evolution were 3.2 % and 9.7 % per patient and were associated with tumour size >4 cm (P = 0.005). The disease-free survival rates were 88.3 % and 61.9 % at 3 and 5 years. No significant difference in glomerular filtration rates before and after the procedure was observed (P = 0.107). The major complications rate was 5.9 % per session with an increased risk in the case of central locations (P = 0.006). CONCLUSIONS: Percutaneous renal RFA appears to be safe and effective with useful nephron-sparing results. KEY POINTS: • Radiofrequency ablation (RFA) is a well-tolerated technique according to mid-term results. • RFA for malignant renal tumours preserved renal function in high-risk patients. • Mid-term efficacy of RFA was close to that of formal conservative surgery. • Tumour size and central location limit the efficacy and safety of RFA.
OBJECTIVES: To evaluate survival and outcomes after percutaneous radiofrequency ablation (RFA) of malignant renal tumours in high-risk patients with long-term follow-up. METHODS: Between 2002 and 2009, 62 patients (71 tumours), with a median age of 73.5 years (20-87), consecutively treated with RFA under ultrasound or computed tomography guidance for malignant renal tumours were retrospectively selected and prospectively followed until 2012, including 25 patients (40.3 %) with solitary kidney and 7 cystic cancers. Maximal tumour diameters were between 8 and 46 mm (median: 23 mm). RESULTS: Radiofrequency ablation was technically possible for all patients. Mean follow-up was 38.8 months (range: 18-78 months). Primary and secondary technique effectiveness was 95.2 % and 98.4 % per patient respectively. The rates of local tumour progression and metastatic evolution were 3.2 % and 9.7 % per patient and were associated with tumour size >4 cm (P = 0.005). The disease-free survival rates were 88.3 % and 61.9 % at 3 and 5 years. No significant difference in glomerular filtration rates before and after the procedure was observed (P = 0.107). The major complications rate was 5.9 % per session with an increased risk in the case of central locations (P = 0.006). CONCLUSIONS: Percutaneous renal RFA appears to be safe and effective with useful nephron-sparing results. KEY POINTS: • Radiofrequency ablation (RFA) is a well-tolerated technique according to mid-term results. • RFA for malignant renal tumours preserved renal function in high-risk patients. • Mid-term efficacy of RFA was close to that of formal conservative surgery. • Tumour size and central location limit the efficacy and safety of RFA.
Authors: Joseph A Pettus; David M Werle; Weston Saunders; Ashok Hemal; Andrew Karim Kader; David Childs; Ronald J Zagoria Journal: J Endourol Date: 2010-10 Impact factor: 2.942
Authors: Debra A Gervais; Ronald S Arellano; Francis J McGovern; W Scott McDougal; Peter R Mueller Journal: AJR Am J Roentgenol Date: 2005-07 Impact factor: 3.959
Authors: François Cornelis; Xavier Buy; Marc André; Raymond Oyen; Juliette Bouffard-Vercelli; Alfredo Blandino; Julien Auriol; Jean-Michel Correas; Amélie Pluvinage; Simon Freeman; Stephen B Solomon; Nicolas Grenier Journal: Radiology Date: 2011-07-19 Impact factor: 11.105
Authors: Joshua M Stern; Robert Svatek; Sangtae Park; Michael Hermann; Yair Lotan; Arthur I Sagalowsky; Jeffrey A Cadeddu Journal: BJU Int Date: 2007-08 Impact factor: 5.588
Authors: Gladwin C Hui; Kemal Tuncali; Servet Tatli; Paul R Morrison; Stuart G Silverman Journal: J Vasc Interv Radiol Date: 2008-07-21 Impact factor: 3.464
Authors: Jason D Iannuccilli; Damian E Dupuy; Michael D Beland; Jason T Machan; Dragan J Golijanin; William W Mayo-Smith Journal: Eur Radiol Date: 2015-09-15 Impact factor: 5.315
Authors: Noah E Canvasser; Igor Sorokin; Aaron H Lay; Monica S C Morgan; Asim Ozayar; Clayton Trimmer; Jeffrey A Cadeddu Journal: World J Urol Date: 2017-03-02 Impact factor: 4.226
Authors: Francois H Cornelis; Jeremy C Durack; Simon Y Kimm; Thomas Wimmer; Jonathan A Coleman; Stephen B Solomon; Govindarajan Srimathveeravalli Journal: Cardiovasc Intervent Radiol Date: 2017-05-17 Impact factor: 2.740